iRhythm Technologies Faces Investor Investigation Following Q3 Earnings Miss and Guidance Update

iRhythm Technologies reported third-quarter 2026 revenue of $221.6 million, below analyst consensus, while Zio AT sales were flat year over year. Management said portfolio integration challenges following its VitalConnect acquisition contributed to the sales slowdown and delayed the FDA submission for its next-generation Zio MCT device until 2027. The disclosures prompted a significant decline in the company’s shares and a potential securities investigation.